Results 101 to 110 of about 5,687 (195)

Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk

Acta Haematologica Polonica
Acalabrutinib belongs to a class of Bruton’s tyrosine kinase inhibitors (BTKis) which have become one of the most widely used drugs for the treatment of B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...
Anna Ewa Wolska-Washer, Tadeusz Robak
doaj   +1 more source

Evolution of BTK inhibitors [PDF]

The purpose of this clinical review evaluates the evolution of bruton’s tyrosine kinase (BTK) inhibitors in becoming the standard of care in treating chronic lymphocytic leukemia (CLL).
Mathew, Dena
core   +2 more sources

Acalabrutinib [PDF]

Reactions Weekly, 2020
  +4 more sources

Physiologically Based Pharmacokinetic Modeling to Assess Antiretroviral–BTK Inhibitor Interactions and Provide Recommendations for Co-Administration Regimens

Pharmaceutics
Objectives: The co-administration of Bruton’s tyrosine kinase (BTK) inhibitors with antiretroviral drugs is challenging due to potential drug–drug interactions (DDIs). However, clinical trials specifically assessing such DDIs are lacking.
Lu Chen, Xiaoxiao Wang, Lixian Li, Yi Yang, Yao Liu, Wanyi Chen   +5 more
doaj   +1 more source

Acalabrutinib

Reactions Weekly, 2022
  +4 more sources

Bruton’s tyrosine kinase inhibition limits endotoxic shock by suppressing IL-6 production by marginal zone B cells in mice

Frontiers in Immunology
Sepsis is a systemic inflammatory response to a severe, life-threatening infection with organ dysfunction. Although there is no effective treatment for this fatal illness, a deeper understanding of the pathophysiological basis of sepsis and its ...
Kazuhiko Kawata, Shinya Hatano, Akemi Baba, Keisuke Imabayashi, Yoshihiro Baba   +4 more
doaj   +1 more source

Analysis of ventricular arrhythmias and sudden death from prospective, randomized clinical trials of acalabrutinib [PDF]

This analysis investigated the incidence of sudden deaths (SDs) and non-fatal and fatal ventricular arrhythmias (VAs) in five acalabrutinib clinical trials. In total, 1299 patients received acalabrutinib (exposure, 4568.4 patient-years).
Bajwa N., Ghia P., Miranda P., Rule S., Seymour J. F., Sharman J. P., Shaw B.   +6 more
core   +1 more source

Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia

Hematology Reports
The treatment landscape of chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults, is constantly changing. CLL patients can be divided into three risk categories, based on their IGHV mutational status and the occurrence of TP53 ...
Samir Mouhssine, Nawar Maher, Sreekar Kogila, Claudio Cerchione, Giovanni Martinelli, Gianluca Gaidano   +5 more
doaj   +1 more source

Move along, nothing to see here: Btk inhibitors stop platelets sticking to plaques [PDF]

, 2018
Busygina, Bye, Bye, Byrd, Jamasbi, Levade   +5 more
core   +1 more source

Treatment Sequencing in Chronic Lymphocytic Leukemia in 2024: Where We Are and Where We Are Headed [PDF]

As treatments with BTK inhibitors and BCL2 inhibitors have replaced the use of chemoimmunotherapy in CLL in both first-line and relapsed patients, it becomes critical to rationalize their use and exploit the full potential of each drug.
Alberto Fresa, Annamaria Tomasso, Antonio Mosca, Francesco Autore, Francesco Iadevaia, Idanna Innocenti, Luca Laurenti, Luca Stirparo, Paolo Ghia   +8 more
core   +2 more sources